| abstract |
The present invention relates to quinoline / quinoxaline compounds that inhibit platelet-induced growth factor tyrosine kinases and / or Lck tyrosine kinases, pharmaceutical compositions comprising such compounds, and cell differentiation, proliferation, extracellular epilepsy production or mediator release and / or Or to the use of such compounds for treating patients susceptible to or susceptible to diseases / conditions associated with T cell activation and proliferation. |